» Articles » PMID: 21651700

Applying a System Approach to Forecast the Total Hepatitis C Virus-infected Population Size: Model Validation Using US Data

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2011 Jun 10
PMID 21651700
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatitis C virus (HCV) infection is associated with chronic progressive liver disease. Its global epidemiology is still not well ascertained and its impact will be confronted with a higher burden in the next decade.

Aim: The goal of this study was to develop a tool that can be used to predict the future prevalence of the disease in different countries and, more importantly, to understand the cause and effect relationship between the key assumptions and future trends.

Methods: A system approach was used to build a simulation model where each population was modeled with the appropriate inflows and outflows. Sensitivity analysis was used to identify the key drivers of future prevalence.

Results: The total HCV-infected population in the US was estimated to decline 24% from 3.15 million in 2005 to 2.47 million in 2021, while disease burden will increase as the remaining infected population ages. During the same period, the mortality rate was forecasted to increase from 2.1 to 3.1%. The diagnosed population was 50% of the total infections, while less than 2% of the total infections were treated.

Conclusion: We have created a framework to evaluate the HCV-infected populations in countries around the world. This model may help assess the impact of policies to meet the challenges predicted by the evolution of HCV infection and disease. This prediction tool may help to target new public health strategies.

Citing Articles

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control.

Joharji H, Alkortas D, Ajlan A, Ahmed M, Al-Ashgar H, Al-Quaiz M Health Sci Rep. 2022; 6(1):e980.

PMID: 36514327 PMC: 9731361. DOI: 10.1002/hsr2.980.


Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress.

Blach S, Brown K, Brown R, Gholam P, Terrault N, Estes C J Infect Public Health. 2022; 16(1):64-70.

PMID: 36473359 PMC: 9674561. DOI: 10.1016/j.jiph.2022.11.021.


Country versus pharmaceutical company interests for hepatitis C treatment.

Lothan R, Gutman N, Yamin D Health Care Manag Sci. 2022; 25(4):725-749.

PMID: 36001218 PMC: 9399601. DOI: 10.1007/s10729-022-09607-2.


Demographics of hepatitis C virus today.

Gonzalez S, Davis G Clin Liver Dis (Hoboken). 2019; 1(1):2-5.

PMID: 31186836 PMC: 6490694. DOI: 10.1002/cld.3.


A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada.

Greenaway C, Azoulay L, Allard R, Cox J, Tran V, Abou Chakra C BMC Infect Dis. 2017; 17(1):140.

PMID: 28193199 PMC: 5307836. DOI: 10.1186/s12879-017-2242-y.